Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer

PRIVATEJul 25, 2024

Position

Chief Executive Officer

Company

Terremoto Biosciences

Charles Baum

cbaum@terremotobio.com

San FranciscoInformation TechnologyBiotechnologyScience And Engineering

Description

Terremoto Biosciences has announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer. Dr. Baum succeeds Peter Thompson, M.D., who will continue to serve as Terremoto’s Board chairperson.

Other recent leadership changes in Science And Engineering and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Exai Bio Appoints Dave Daly as Chief Executive Officer (July 24, 2024)
HAYA Therapeutics Names Eric Adam as Chief Operating Officer (July 18, 2024)
Atavistik Bio Appoints Paul Bruno, Ph.D. as Chief Business Officer (August 12, 2024)
Asymchem Welcomes Dr. Cheng Yi Chen as Chief Technical Officer (CTO) for Small Molecule Market (June 26, 2024)
MOMA Therapeutics Appoints Marc Ballas as SVP, Head of Clinical Development, and Adam Thomas as Chief People and Experience Officer (June 25, 2024)
Electrasteel Inc. Appoints James Rutland as Chief Financial Officer and Steve MacManus as Vice President of Engineering (August 29, 2024)

Who to call at Terremoto Biosciences, and when

A new leader at Terremoto Biosciences brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Terremoto Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Terremoto Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Terremoto Biosciences. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Terremoto Biosciences

Location

San Francisco, California, United States

About

Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Terremoto Biosciences changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans